(S)-1-Dimethylamino-2-butanol | 34487-38-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (S)-1-Dimethylamino-2-butanol
• 英文别名: (+)-1-Dimethylamino-2-butanol；(2S)-1-(Dimethylamino)-2-butanol；(2S)-1-(dimethylamino)butan-2-ol
• CAS: 34487-38-2
• 化学式: C₆H₁₅NO
• 分子量: 117.191
• InChiKey: ZABFSYBSTIHNAE-LURJTMIESA-N

物化性质

• 沸点：
  157.8±13.0 °C(Predicted)
• 密度：
  0.883±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-1-Dimethylamino-2-butanol 、 碘甲烷 以 甲醇 为溶剂， 反应 5.0h， 以100%的产率得到((S)-2-Hydroxy-butyl)-trimethyl-ammonium; iodide
  参考文献：
  名称：

  Improved Procedure for the Preparation of Chiral 1,2-Epoxybutanes: Total Synthesis of (S)-3′-Hydroxy-Δ⁹-tetrahydrocannabinol, A Highly Active Metabolite of Δ⁹-Tetrahydrocannabinol

  摘要：

  DOI：

  10.1055/s-1984-30884
• 作为产物：
  描述：

  聚合甲醛 、 1-nitro-2-butanol 在 palladium on activated charcoal 甲酸 、 氢气 作用下， 以 水 为溶剂， 生成 (S)-1-Dimethylamino-2-butanol
  参考文献：
  名称：

  β-取代的乙酰胆碱碘化物的制备及活性

  摘要：

  （-）-和（+）-乙酰基β-乙基胆碱碘化物的对映异构体是根据（-）从（+）-酒石酸和（+）-溴樟脑-磺酸中分离出1-二甲氨基-2-丁醇而制得的。 ）和（+）异构体。（-）-对映异构体的绝对构型通过由R（-）-2-羟基丁酸合成（-）-乙酰基β-乙基胆碱碘化物来确定。由旋光的扁桃酸制备旋光的乙酰基β-苯基胆碱碘化物。这些对映异构体表明，R（-）异构体对乙酰胆碱酯酶受体具有更高的亲和力，而S（+）异构体是对豚鼠回肠的更强效激动剂。

  DOI：

  10.1002/jps.2600601144

文献信息

• Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators
  申请人：Henneböhle Marco

  公开号：US20100249093A1

  公开（公告）日：2010-09-30

  The present invention relates to substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amyotrophic lateral sclerosis (ALS), anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

  本发明涉及取代杂环基哌啶衍生物作为黑色素-4受体调节剂。根据化合物的结构和立体化学，本发明的化合物可以是人类黑色素-4受体（MC-4R）的选择性激动剂或选择性拮抗剂。激动剂可用于治疗肥胖症、糖尿病和性功能障碍等疾病和疾病，而拮抗剂可用于治疗癌症消耗症、肌肉萎缩、厌食症、肌萎缩侧索硬化症（ALS）、焦虑和抑郁症等疾病和疾病。通常，涉及MC-4R调节的所有疾病和疾病都可以用本发明的化合物治疗。
• SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS
  申请人：Santhera Pharmaceuticals (Schweiz) AG

  公开号：EP2176250A1

  公开（公告）日：2010-04-21
• TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF
  申请人：Purdue Pharma L.P.

  公开号：US20160355499A1

  公开（公告）日：2016-12-08

  The invention relates to compounds of formula IA and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof.
• [EN] SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS D'HÉTÉROARYLPIPÉRIDINE SUBSTITUÉS UTILISÉS COMME MODULATEURS DU RÉCEPTEUR 4 DE LA MÉLANOCORTINE
  申请人：SANTHERA PHARMACEUTICALS CH

  公开号：WO2009010299A1

  公开（公告）日：2009-01-22

  The present invention relates to substituted heteroarylpiperidine derivative (I) as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amyotrophic lateral sclerosis (ALS), anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.
• [EN] PRMT5 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PRMT5 ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2015200680A2

  公开（公告）日：2015-12-30

  Described herein are compounds of Formula (I)-(XIII), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.